FDA Approved: VITRAKVI — Supplemental Application (Loxo Oncology, Inc.)

View source ↗

Summary

FDA approved a supplemental application for VITRAKVI (larotrectinib) expanding its indication to TRK fusion-positive solid tumors in adults and children.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Trk Fusion-positive Solid Tumors

Drugs mentioned

• Vitrakvi (larotrectinib)

Snippet

SUPPL AP for VITRAKVI (LAROTRECTINIB)